AFM
RKDA icon

Anson Funds Management’s Arcadia Biosciences RKDA Stock Holding History

Anson Funds Management’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,383
Closed -$175K – 43
2018
Q4 		$175K Buy
+1,383
New +$232K 0.1% 42

Other funds holding RKDA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Anson Funds Management's RKDA Position: Q1 2019 in Review

Anson Funds Management sold out of Arcadia Biosciences (RKDA) in Q1 2019, closing a stake of 1,383 shares — an estimated $175K sold.

Anson Funds Management first reported a position in RKDA in Q4 2018 and held it in 1 quarter. The position peaked at $175K in Q4 2018. 12 funds tracked by Wall St. Rank hold RKDA as of Q1 2019.

  • Anson Funds Management reported no remaining Arcadia Biosciences position as of Q1 2019 after selling out during the quarter.
  • Anson Funds Management sold 1,383 Arcadia Biosciences shares in Q1 2019, an estimated $175K.
  • Anson Funds Management first reported a position in Arcadia Biosciences in Q4 2018 and held it in 1 quarter.
  • Anson Funds Management's Arcadia Biosciences position peaked at $175K in Q4 2018.
  • 12 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q1 2019.

Based on Anson Funds Management's 13F filing for Q1 2019, filed 15 May 2019.